{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-118338","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.866710+00:00","generated_at":"2026-05-30T00:35:16.113825+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TriSalus Q3 revenue up 42% to $7.3M; guides for 50%+ growth and positive EBITDA in 2025","bullets":["Q3 revenue $7.3M (+42% YoY); nine-month revenue $21.2M (+66% YoY). Gross margin 86%.","Operating loss improved to $8.7M (Q3) and $28.6M (9M) from $18.6M and $40.2M in 2023.","Net loss per share $0.12 (Q3) vs $0.14; cash $11.3M plus $25M OrbiMed facility.","2025 guidance: >50% revenue growth, >20% opex reduction, positive full-year EBITDA, H2 cash flow positive.","Launched TriNav LV system and TriGuide catheter; initiated PROTECT trial for thyroid embolization ($400M market)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-118338","json":"https://secwatch.observer/filing/0001104659-24-118338.json","markdown":"https://secwatch.observer/filing/0001104659-24-118338.md","text":"https://secwatch.observer/filing/0001104659-24-118338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924118338/0001104659-24-118338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924118338/tm2428379d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:35:16.113825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}